October 8, 2021 8:10am

With the September jobs report due before the open with the fed hovering to slow its bond purchasing as the Nasdaq and Nasdaq 100 had hit resistance at the 21-day line

Pre-open indications: 3 BUYs, 3 SELL and 1 Pump (or No Promote)

Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.

 

Dow futures are UP +0.08% (+26 points), S&P futures are UP +0.11% (+5 point) and NASDAQ futures are UP +0.14% (+21 point)

 

U.S. stock index futures were little changed during early trading Friday awaiting the September jobs report,

European markets were down awaiting U.S. numbers,

Asia Pacific markets were mixed as China turned from holiday; Japan was up while South Korea tanked

 

Henry’omics:

Thursday’s stock market rally started off strong, then backed off somewhat from intraday highs as Friday rolls ...

Today, “Economists expect the September jobs report to show nonfarm payrolls gain of 475,000, with the jobless rate dipping to 5.1%. Investors will want to see a pickup in hiring from August's 235,000 jobs to show that the economic recovery is on track. But too-fast hiring could send Treasury yields sharply higher and raise expectations for a faster Fed bond taper.” <IBD)

A well-received jobs report could be the trigger for a high-volume advance, but it could be a high-volume retreat as well.

 

Economic data Docket: key September jobs (non-farm payroll) report which will be key as the Fed prepares to slow its $120 billion-per-month bond-buying program.

 

If you didn’t remember what happen at Thursday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

  • Thursday’s evening’s recap: “the oversold were ripe to be picked. I also wrote, “investors should take a shot or roll the dice for possible profits or loss as some gains are suspect” … https://www.regmedinvestors.com/articles/12129

Q4: October, 2 positive and 3 negative closes

Q3/21:

  • September, 1 holiday, 10 positive and 10 negative close
  • August - 12 positive and 10 negative close
  • July: 6 positives, 1 holiday and 15 negative closes

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Pump or no promote:

Biostage (BSTG) closed up +$0.19 to $3.21 with 612 shares traded after Wednesday’s -$0.02 to $3.02, Tuesday’s -$0.59 following Monday’s +$0.59. For a company with NO clinical trial, a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation – so what’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?

 

SELL into Strength

CRISPR Therapeutics (CRSP) closed up +$1.00 to $102.99 after Wednesday’s -$0.50 to $101.99, Tuesday’s $102.49, Monday’s $102.43 and last Friday’s $111.29 with a negative -$0.60 or -0.58% pre-market indication.

Editas Medicine (EDIT) closed up +$1.49 to $39.03, Wednesday’s $37.54, Tuesday’s $38.23, Monday $37.29 and last Friday’s $39.91 with a -$1.16 or -2.97% pre-market indication

Intellia Therapeutics (NTLA) closed up again +$5.09 to $134.78 after Wednesday’s +$0.07 to $129.69, Tuesday’s +$2.98 to $129.76 and Monday’s -$7.28 to $126.78, with a negative -$2.56 or -1.90% pre-market indication.

 

BUY:

Fate Therapeutics (FATE) closed down again -$0.79 to $56.33 after Wednesday’s -$0.18 to $57.12, Tuesday’s $57.30 and Monday’s $56.41 with a positive +$0.55 or +0.98% aftermarket indication.

Global Blood Therapeutics (GBT) closed up +$2.40 to $27.81 after Wednesday’s -$0.40 to $25.41, Tuesday’s $25.81 and Monday’s $26.12 with a positive +$0.94 or +3.38% pre-market indication.

Sage Therapeutics (SAGE) closed down -$0.35 to $45.29 after Wednesday’s +$0.62 to $45.64, Tuesday’s $45.02 and Monday’s $44.35 with a positive +$0.20 or +0.44% pre-market indication

 

The BOTTOM LINE: I am NOT taking any action until the market’s direction is confirmed as goes the stem cell and gene therapy sector.

If the sector rally has a follow-through on Friday, be careful in the next weeks – earnings.

Caution keeps that portfolio risk mitigated.

Theme is uncertainty, more likely to me: skepticism …

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.